SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tenaya Therapeutics, a biopharmaceutical company focused on developing potentially curative treatments for heart disease, today announced that it has strengthened its leadership team with the appointment of Whittemore Tingley, M.D., Ph.D., as Chief Medical Officer, and Kee-Hong Kim, Ph.D., as Senior Vice President of Manufacturing and […]
Financial
Itamar Medical Reports Fourth Quarter and Full Year 2018 Financial Results With Record Revenues
CAESAREA, Israel, March 13, 2019 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today reported its unaudited financial results for the fourth quarter and full year 2018. […]
Caladrius Biosciences to Host 2018 Fourth Quarter and Year End Financial Results Conference Call on Thursday, March 14, 2019 at 4:30 p.m. Eastern Time
BASKING RIDGE, N.J., March 13, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses and with a focus on select […]
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) — Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, today announced its financial results for the year ended December 31, 2018, and recent business highlights. “We are looking forward to […]
Correvio Reports Fourth Quarter and Full Year 2018 Financial Results
Company on Track to Resubmit Brinavess NDA in Q2 2019 Mark H.N. Corrigan, MD to Commence CEO Duties on March 14, 2019 Management to Host Conference Call and Webcast Today, March 13, 2019 at 8:00 a.m. Eastern (5:00 a.m. Pacific) NASDAQ: CORV TSX: CORV VANCOUVER, March 13, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical […]
Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21
Conference Call Scheduled for 4:30pm Eastern Time NASDAQ, TSX: NVCN VANCOUVER, March 13, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today […]
Corindus Vascular Robotics Announces Additional Closing of Private Placement
WALTHAM, Mass.–(BUSINESS WIRE)–Corindus Vascular Robotics, Inc. (“Corindus” or the “Company”) [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced the execution of an additional closing of the private placement previously announced on February 26, 2019. In the additional closing, existing investors with preemptive rights purchased an aggregate […]
Catasys Schedules Fourth Quarter 2018 Results Conference Call for March 14, 2019
LOS ANGELES–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ:CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its fourth quarter and year ended December 31, 2018, after the closing of the stock market on Thursday, March 14, 2019. The Company will […]
Stereotaxis Reports 2018 Full Year Financial Results
ST. LOUIS, March 12, 2019 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the fourth quarter and full year ended December 31, 2018. “2018 was an extremely active year at Stereotaxis with progress […]
Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares
VANCOUVER, March 12, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN) announced today that it has entered into exchange agreements (“Exchange Agreements”) with the holders (“Holders”) of all of its outstanding Series A common share purchase warrants and Series E common share purchase warrants (collectively, the “Warrants”) issued pursuant […]



